Build Your CRISPR Workflow for Scalability

If you are exploring mRNA-based editing workflows, optimizing delivery strategies, or thinking ahead about how your workflow may scale over time, this program is designed for you.

You may be:

• evaluating mRNA delivery for the first time
• comparing editor formats or editing systems
• optimizing workflows for reproducibility and consistency
• exploring how manufacturing strategy could impact future development
• looking for earlier alignment between research workflows and future GMP needs

Or maybe you simply want the opportunity to test next-generation CRISPR editors using materials generated from the same manufacturing foundation used for GMP production.

This program gives you the opportunity to evaluate how these editors fit into your workflow today while helping you think more strategically about workflow continuity, scalability, and long-term development flexibility.

What You Receive

Participants selected for the program will receive:

• Access to AccuBase CBE, eSpOT-ON, and hfCas12Max RUO mRNA editors
• Collaborative engagement with Synthego experts throughout the program
• An early look at the manufacturing platform behind Synthego’s GMP CRISPR editor services
• Opportunities to provide feedback on your workflow experience and editor evaluation

AccuBase CBE mRNA

AccuBase CBE is designed to support precise cytosine base editing without introducing double-strand breaks, giving you the ability to make targeted edits while helping reduce risks associated with unwanted DNA damage. As you optimize therapeutic editing workflows, reducing unwanted DNA disruption while maintaining efficient editing activity plays an important role in both workflow performance and safety considerations.

The mRNA format allows you to evaluate transient editor delivery while assessing how base editing workflows integrate into your broader delivery and development strategy.

eSpOT-ON Nuclease mRNA

eSpOT-ON is engineered to support high on-target editing activity while reducing unwanted off-target editing events, helping you achieve strong editing efficiency alongside greater editing precision. If you are developing CRISPR cell and gene therapy workflows, balancing editing performance with specificity plays an important role in both therapeutic effectiveness and overall safety considerations. eSpOT-ON gives you the opportunity to evaluate a next-generation editor designed to support efficient editing while helping reduce concerns around unintended editing activity.

Using the mRNA format also allows you to evaluate transient editor delivery, expression timing, and workflow integration within your existing system.

hfCas12Max Nuclease mRNA

hfCas12Max combines optimized Cas12 activity with high-fidelity engineering to support efficient genome editing while helping reduce unintended editing activity. Its smaller size and broader PAM access may also give you greater flexibility when designing your editing and delivery strategies.

If you are developing CRISPR cell and gene therapy workflows, editing specificity becomes increasingly important as your programs move toward more sensitive applications and greater safety expectations. hfCas12Max gives you the opportunity to evaluate a next-generation Cas12 editor designed to support strong editing performance while providing greater confidence in editing precision and control.

The mRNA format also allows you to assess transient editor delivery, expression timing, and workflow integration within your existing system.

You already know that the workflow decisions you make today can have a major impact on everything that comes next. What’s harder to predict is how those workflows will hold up as your program grows and manufacturing expectations become more complex. That’s part of what makes this program unique.

The RUO mRNA editors provided through the Pilot Validation Program are generated using the same manufacturing platform and process foundation used across Synthego’s GMP CRISPR editor services. That means you’re not just evaluating editor performance in isolation — you’re also gaining earlier exposure to a manufacturing approach designed with scalability, consistency, and long-term workflow continuity in mind.

As your workflow evolves, factors like process consistency, analytical characterization, manufacturing controls, and scalability can start influencing reproducibility and overall workflow performance in ways that may not appear during early research stages.

By working with Synthego earlier, you can start exploring those considerations while your workflow is still flexible and optimization decisions are easier to make. As your CRISPR workflow advances, the manufacturing approach behind your editors becomes just as important as the editing performance itself. Synthego’s GMP manufacturing approach is designed to support:

• scalable production
• analytical rigor and quality oversight
• process consistency across development stages
• smoother transition into future GMP workflows

The Synthego mRNA Pilot Validation Program is designed to give you selective early access to next-generation CRISPR editors while helping you evaluate how your workflow may evolve over time.

Whether your focus is workflow optimization, delivery strategy, scalability, or future manufacturing alignment, this program provides an opportunity to work directly with Synthego scientists while evaluating mRNA editors generated using the same manufacturing foundation used across our GMP services.